Thiago Douberin da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thiago Douberin da Silva has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Charles dos Santos Macêdo
Laboratory of Advances in Protein Biotechnology (LABIOPROT), LIBAS-Integrated Multi-User Laboratory in Applied Biotechnology, Institute of Biological Sciences, University of Pernambuco, Recife 50100-130, PE, Brazil
3 shared publications - Michelly Cristiny Pereira
Universidade Federal de Pernambuco
3 shared publications - Antônio Guedes Correia Gondim Filho
Universidade Federal de Pernambuco
1 shared publication - Bruna Pereira da Silva
Universidade Federal de Pernambuco
1 shared publication - Carolina Barbosa Brito da Matta
Universidade Federal de Pernambuco
1 shared publication - Danielle Rocha Silva
Faculdade Santa Maria
1 shared publication
Latest Publications
- Open Access
- 28 December 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (1)
Análise das prescrições de albumina humana 20% de um hospital escola e sua respectiva descrição de gastos
Albumin is the most important plasma expander in the bloodstream. In the form of medication, it must be prescribed after a thorough evaluation of the patients, basing its use according to the literature, as it has contraindications, such as bleeding in post-surgical patients, in addition to being a high-cost medication. Thus, the objective of this work was to carry out a survey of the therapeutic indications contained in the prescriptions of human albumin (HA) 20% of a Teaching Hospital in the city of Recife, Pernambuco, Brazil, in order to assess whether such indications have scientific basis, in addition to a survey of the costs related to the acquisition of this drug should be carried out. A cross-sectional, retrospective study was carried out, based on the analysis of prescriptions prescribed to patients, from May 2015 to May 2017. The therapeutic indications found were: relief paracentesis (29%), hepatorenal syndrome (HRS) (22,9%), hypovolemia (20.6%), septic shock (8.7%), spontaneous bacterial peritonitis (SBP) (6.4%), hypoalbuminemia (6.1%), ascites (4.1%), neoplasia (1.2%) and hepatic encephalopathy (HE) (0.6%). After a literature review, HA 20% has scientific support for the treatment of paracentesis, SHR and PBE, which corresponds to 63.1% of prescriptions and has no scientific support for the treatment of hypovolemia, septic shock, hypoalbuminemia, cancer and HE (36.9%), which can be replaced by other plasma expanders. Thus, the importance of basing the prescription of 20% HA according to the literature is highlighted, always aiming at the rational use of medicines.
- 28 December 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (1)
Open AccessAnálise das prescrições de albumina humana 20% de um hospital escola e sua respectiva descrição de gastos
Albumin is the most important plasma expander in the bloodstream. In the form of medication, it must be prescribed after a thorough evaluation of the patients, basing its use according to the literature, as it has contraindications, such as bleeding in post-surgical patients, in addition to being a high-cost medication. Thus, the objective of this work was to carry out a survey of the therapeutic indications contained in the prescriptions of human albumin (HA) 20% of a Teaching Hospital in the city of Recife, Pernambuco, Brazil, in order to assess whether such indications have scientific basis, in addition to a survey of the costs related to the acquisition of this drug should be carried out. A cross-sectional, retrospective study was carried out, based on the analysis of prescriptions prescribed to patients, from May 2015 to May 2017. The therapeutic indications found were: relief paracentesis (29%), hepatorenal syndrome (HRS) (22,9%), hypovolemia (20.6%), septic shock (8.7%), spontaneous bacterial peritonitis (SBP) (6.4%), hypoalbuminemia (6.1%), ascites (4.1%), neoplasia (1.2%) and hepatic encephalopathy (HE) (0.6%). After a literature review, HA 20% has scientific support for the treatment of paracentesis, SHR and PBE, which corresponds to 63.1% of prescriptions and has no scientific support for the treatment of hypovolemia, septic shock, hypoalbuminemia, cancer and HE (36.9%), which can be replaced by other plasma expanders. Thus, the importance of basing the prescription of 20% HA according to the literature is highlighted, always aiming at the rational use of medicines.
- Open Access
- 4 December 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (16)
Análise sobre a sustentabilidade financeira para garantia do acesso integral aos medicamentos oncológicos
A alta incidência dos casos de câncer tornou-o evidente problema de saúde pública em todo o mundo. Os gestores da rede pública no Brasil alegam que os recursos repassados não são suficientes para cobrir os custos com os quimioterápicos. Este trabalho trouxe um panorama do serviço ofertado pelo SUS na rede de atenção oncológica em Pernambuco e avaliou a sustentabilidade financeira para garantir o acesso aos medicamentos quimioterápicos em um hospital referência. Tratou-se de um estudo observacional, analítico e retrospectivo, realizado no período de 2015 a 2020. Avaliou-se o custo dos quimioterápicos para o câncer de mama e foram analisadas as incorporações de novos tratamentos pela CONITEC durante o mesmo período. Foram realizados 343.585 procedimentos quimioterápicos nos estabelecimentos avaliados e observou-se que o câncer de mama foi a neoplasia mais onerosa. Observou-se ainda que o financiamento dos tratamentos oncológicos se manteve estável, apesar da evolução inflacionária e epidemiológica, havendo prejuízo na incorporação de tecnologias. Verificou-se que os custos com quimioterápicos para câncer de mama comprometeram 31,23% do valor pago pelo MS, e atualmente, com os reajustes do período, este passou a comprometer 100,75%. Ao projetar os reajustes para os próximos anos, verificou-se que o orçamento estaria comprometido em 121,6%, levando em conta o mesmo cenário inflacionário. Concluiu-se que a atual forma de financiamento do tratamento quimioterápico para o câncer de mama não se mostrou financeiramente sustentável no cenário avaliado e que se novos investimentos não forem aportados, os pacientes do SUS não serão beneficiados com as novas tecnologias de tratamento.
- 4 December 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (16)
Open AccessAnálise sobre a sustentabilidade financeira para garantia do acesso integral aos medicamentos oncológicos
A alta incidência dos casos de câncer tornou-o evidente problema de saúde pública em todo o mundo. Os gestores da rede pública no Brasil alegam que os recursos repassados não são suficientes para cobrir os custos com os quimioterápicos. Este trabalho trouxe um panorama do serviço ofertado pelo SUS na rede de atenção oncológica em Pernambuco e avaliou a sustentabilidade financeira para garantir o acesso aos medicamentos quimioterápicos em um hospital referência. Tratou-se de um estudo observacional, analítico e retrospectivo, realizado no período de 2015 a 2020. Avaliou-se o custo dos quimioterápicos para o câncer de mama e foram analisadas as incorporações de novos tratamentos pela CONITEC durante o mesmo período. Foram realizados 343.585 procedimentos quimioterápicos nos estabelecimentos avaliados e observou-se que o câncer de mama foi a neoplasia mais onerosa. Observou-se ainda que o financiamento dos tratamentos oncológicos se manteve estável, apesar da evolução inflacionária e epidemiológica, havendo prejuízo na incorporação de tecnologias. Verificou-se que os custos com quimioterápicos para câncer de mama comprometeram 31,23% do valor pago pelo MS, e atualmente, com os reajustes do período, este passou a comprometer 100,75%. Ao projetar os reajustes para os próximos anos, verificou-se que o orçamento estaria comprometido em 121,6%, levando em conta o mesmo cenário inflacionário. Concluiu-se que a atual forma de financiamento do tratamento quimioterápico para o câncer de mama não se mostrou financeiramente sustentável no cenário avaliado e que se novos investimentos não forem aportados, os pacientes do SUS não serão beneficiados com as novas tecnologias de tratamento.
- Open Access
- 10 June 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (7)
Systematic assessment of the drugs cold chain in Brazil by pharmaceutical professionals
One of the challenges in pharmaceutical logistics is to ensure that thermolabile drugs reach the patient with quality. This prospective cross-sectional study aimed to analyze the current cold chain scenario in Brazil. A semi-structured electronic questionnaire was applied for data collection. The total sample was 1793 pharmacists (CI: 99.998%; ME: 5%; p: 0.00002). 74.1% of the pharmacists reported that transportation is the most critical stage; 97.2% stated that the chosen mode influences the quality of the products; 52.5% reported only having partial parameters (tools) for the assessment of quality and that thermolabile medications possibly arrive altered to the final consumer due to the cold chain (59.8%); 66.9% do not have specific training on thermolabile medicines and 50.9% did not receive the technical data sheets of the products through the registration holders; 20.7% reported not being able to analyze or perform any activity related to qualification and validation. The absence of markings in the manual records (50.6%), the non-validation of the equipment used for conservation (30.6%) and the incorrect storage of medicines at domestic refrigerators (45.5%), near food (35.8%), were also noted. The non-measurement of the temperature of the products received was affirmed by 56.7%, as well as the use of thermometers to measure parameters (45.3%); 58.7% of the establishments do not have thermal mapping and 55.3% of the professionals are unaware of the thermal durability of the packaging. Due potentially inadequate situation, there is urgency to implement tools that guarantee the quality of thermolabile drugs in all its logistical stages.
- 10 June 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (7)
Open AccessSystematic assessment of the drugs cold chain in Brazil by pharmaceutical professionals
One of the challenges in pharmaceutical logistics is to ensure that thermolabile drugs reach the patient with quality. This prospective cross-sectional study aimed to analyze the current cold chain scenario in Brazil. A semi-structured electronic questionnaire was applied for data collection. The total sample was 1793 pharmacists (CI: 99.998%; ME: 5%; p: 0.00002). 74.1% of the pharmacists reported that transportation is the most critical stage; 97.2% stated that the chosen mode influences the quality of the products; 52.5% reported only having partial parameters (tools) for the assessment of quality and that thermolabile medications possibly arrive altered to the final consumer due to the cold chain (59.8%); 66.9% do not have specific training on thermolabile medicines and 50.9% did not receive the technical data sheets of the products through the registration holders; 20.7% reported not being able to analyze or perform any activity related to qualification and validation. The absence of markings in the manual records (50.6%), the non-validation of the equipment used for conservation (30.6%) and the incorrect storage of medicines at domestic refrigerators (45.5%), near food (35.8%), were also noted. The non-measurement of the temperature of the products received was affirmed by 56.7%, as well as the use of thermometers to measure parameters (45.3%); 58.7% of the establishments do not have thermal mapping and 55.3% of the professionals are unaware of the thermal durability of the packaging. Due potentially inadequate situation, there is urgency to implement tools that guarantee the quality of thermolabile drugs in all its logistical stages.